Mortality in the UK STRIDER trial of sildenafil therapy for the treatment of severe early-onset fetal growth restriction

Severe early-onset fetal growth restriction (FGR) is an untreatable condition associated with significant mortality and morbidity for the fetus and neonate. There has been growing interest in novel therapies such as nitic oxide donors/promotors to improve placental function and outcomes for these high-risk pregnancies. The recently published STRIDER UK trial was designed to test the effectiveness of sildenafil (25mg three times a day) versus placebo at prolonging gestation in severe early-onset.